[ad_1]

Corindus Vascular Robotics is in the healthcare sector and is in the medical devices industry. The company CEO is Mark J. Toland. Corindus Vascular Robotics Inc is engaged in the design, manufacture, and sale of precision vascular robotic-assisted systems for use in interventional vascular procedures the CorPath System. Its product includes the CorPath 200 and CorPath GRX Systems.

Previous Intraday Trading Performance:

The CVRS stock showed a previous change of -0.94% with an open at 2.14 and a close of 2.11. It reached an intraday high of 2.24 and a low of 2.06.

Business Wire:  Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

Liquidity:

The stock has a market cap of $435.1m with 206.2m shares outstanding, of which the float is 205.4m shares. Trading volume reached 680,099 shares compared to its average volume of 1,441,441 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Corindus Vascular Robotics shares returned 4.46% and in the past 30 trading days it returned -11.34%. Over three months, it changed 77.31%. In one year it has changed 102.88% and within that year its 52-week high was 2.54 and its 52-week low was 0.70. CVRS stock is 201.39% above its 52 Week Low.

Our calculations show a 200 day moving average of 1.32 and a 50 day moving average of 1.82. Currently CVRS stock is trading 59.73% above its 200 day moving average.

Business Wire:  Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

Earnings:

The last annual fiscal EPS for the company was reported at -0.22 that ended on 31st of December 2018.

Indicators to Watch:

Based on the latest filings, there is 40.40% of institutional ownership. Short-interest is 14,433,050, which is 7.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 7.26. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 1.97

PR Newswire:  Cooper Standard Reports First Quarter Results, Reaffirms Adjusted EBITDA Guidance and Announces Two Significant New Fortrex(TM) Technology Agreements

Fundamental Indicators:

Based on last reported financials, the company’s return on assets is -149.52%, price-to-sales is 47.25 and price-to-book is 85.24.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 0  :Past Performance Score
 2  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

[ad_2]

Source link